Gilead Sciences blood cancer therapy trials put on hold by USFDA
The drug is an antibody treatment that blocks a type of protein, called CD47, which helps damaged cells avoid destruction by the immune system.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-08 07:00 GMT | Update On 2024-03-22 09:00 GMT
Gilead Sciences said on Wednesday the U.S. Food and Drug Administration had put a hold on trials testing the company's blood cancer drug following increased risk of patient death in some studies.
The company will stop testing the drug, magrolimab, for all blood cancers and will review its safety across other studies such as those in patients with colon and breast cancers.
Gilead gained access to the drug through its $4.9 billion purchase of Forty Seven Inc in 2020.
The drug is an antibody treatment that blocks a type of protein, called CD47, which helps damaged cells avoid destruction by the immune system.
An analysis of a late-stage trial and other studies showed an increased risk of death, the company said, adding it also showed that the drug was unlikely to succeed in the trials.
The company had discontinued the study of the drug in combination with a type of chemotherapy in patients with a higher risk of myelodysplastic syndromes in July.
I-mab, Innovent Biologics, Akeso are among companies looking to develop similar class of drug for cancer.
Read also: Gilead Sciences appoints Ted Love to Board of Directors
Original source link: https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-puts-hold-gileads-blood-cancer-therapy-trials-2024-02-07/#:~:text=Feb 7 (Reuters) - Gilead,patient death in some studies.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd